Top in hem/onc: FDA pauses gene therapy trial, breakthrough COVID-19 infections
Click Here to Manage Email Alerts
The FDA halted a phase 3 study that was evaluating an investigational gene therapy for a rare neurological disease in young children.
Healio’s coverage of the announcement was the top story in hematology/oncology last week.
Photo source: Adobe Stock
Another top story contained data that indicated certain blood cancers could put patients at risk for breakthrough COVID-19 infections.
Read these and more top stories in hematology/oncology below:
FDA halts trial of gene therapy for rare neurological disease due to cancer risk
The FDA placed a clinical hold on a phase 3 study designed to evaluate elivaldogene autotemcel, an investigational gene therapy, for the treatment of younger patients with cerebral adrenoleukodystrophy. Read more.
Patients with certain blood cancers may be at risk for breakthrough COVID-19 infections
Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell. Read more.
Financial lessons learned from COVID-19 pandemic
With summer 2021 here, more than 150 million Americans vaccinated for COVID-19, sports played in full arenas and many activities nearly back to normal, a column on financial lessons that can be learn from the pandemic is needed. Read more.
Researcher receives recognition for work to ‘move the dial’ on health equity
Cancer Health, an online resource for patients with cancer, recognized Erin Kobetz, PhD, MPH, for her research on identifying and overcoming racial disparities in health care. Read more.
FDA approves Keytruda-Lenvima combination for advanced renal cell carcinoma
The FDA approved the combination of pembrolizumab and lenvatinib for first-line treatment of adults with advanced renal cell carcinoma. Read more.